Table 1

The clinical and pathologic features of the ovarian fibrosarcoma cases examined

Reference

Case No.

Age

Symptom

FIGO stage

Largest diameter (cm)

Mitoses/10 HPFs

CD10

Ki-67 (MIB-1) positive

Vimentin

CD117

SMA

Des

EMA

S-100

CD99

CD34

α-inhibin

ER

PR

CA125 U/ml

Therapy

Recurrence

Follow-up (months)


Interval (months)

Site

Treatment


China Case 1[6]

1

43

AP

III c

10

≥ 4

(-)

50%-75%

(+)

(-)

(-)

/

/

(-)

(-)

/

(-)

(-)

(-)

/

OR

1

Pelvis

BAO

Died (4)

China Case 2 [7]

2

39

AP

I a

11

5~7

(-)

85%

(+)

/

(-)

(-)

(-)

(-)

(-)

/

(-)

(-)

(-)

/

BAO

NP

NP

NP

TF (14)

China Case 3

3

53

NP

I a

10

3~7

/

/

(+)

/

(-)

(-)

(-)

(-)

(-)

/

(-)

(-)

(-)

68.45

BAO

NP

NP

NP

TF (12)

China Case 4

4

20

NP

II a

7

3~5

/

15%

(+)

(-)

(-)

(-)

(-)

(-)

(-)

/

(-)

/

/

/

BAO

6

Pelvis

CT

Died (10)

China Case 5[8]

5

56

NP

III c

16

13

(-)

25%

(+)

(-)

(-)

(-)

(-)

(-)

(-)

(-)

/

/

/

< 35

BAO+(IA+DTIC)

NP

NP

NP

TF (8)

China Case 6[9]

6

43

NP

I a

5.7

16

(-)

> 10%

(+)

/

(-)

/

/

(-)

/

(-)

(+)

/

/

< 35

BAO+PVB

NP

NP

NP

TF (7)

China Case 7 [10]

7

21

AP

III b

15

≥ 4

/

> 10%

(+)

/

/

/

/

/

/

/

/

/

/

/

OR

3

Pelvis

NP

Died (6)

China Case 8

8

66

AP

II b

11

8

/

15%

(+)

/

(-)

(-)

(-)

(-)

/

/

(-)

/

/

/

BAO

10

Sigmoid

SS+CT

Died (23)

China Case 9

9

37

AP

II c

/

≥ 4

(+)

20%

(+)

(-)

(-)

(-)

(-)

(-)

/

(-)

(-)

(-)

(-)

198

BAO+(IA+DTIC)

NP

NP

NP

TF (15)

China Case 10

10

44

AP

III b

13

23

(-)

75%

(+)

/

(-)

/

/

(-)

/

/

(-)

/

/

/

OR

1

Pelvis

NP

Died (3)

China Case 11

11

52

AP

II b

12

14

/

< 5%

/

/

/

/

/

/

/

/

/

/

/

/

BAO+IAP

16

Pelvis

CT

Alive with tumor (34)

China Case 12

12

48

NP

I a

8

3~4

(-)

< 5%

(+)

/

(-)

(-)

/

(-)

/

/

(-)

/

/

/

BAO+IAP

NP

NP

NP

TF (45)

China Case 13

13

61

AP

III b

15

18

/

60%

(+)

/

(+)

(-)

(-)

(-)

/

/

(+)

/

/

/

OR

2

Pelvis

NP

Died (11)

Lee et al. [17]

14

69

VB

I

6

6~8

/

> 10%

/

/

/

/

/

/

/

/

(+)

/

/

/

BAO

/

/

/

/

Kruger et al. [18]

15

32

NP

I

7

8

/

5%-10%

/

/

/

(-)

(-)

(-)

/

(-)

/

/

/

116.1

OR

NP

NP

NP

TF (12)

Choi et al. [19]

16

44

AP

I a

18

17

/

< 1%

(+)

/

(-)

/

/

(-)

/

/

/

(-)

(-)

/

BAO+AP

NP

NP

NP

TF (120)

17

34

AP

I b

13

8

/

20%

(+)

/

(-)

/

/

(-)

/

/

/

(+)

(+)

26.5

BAO+(VP16+IP)

NP

NP

NP

TF (60)

Testa et al. [20]

18

44

NP

III b

/

7

/

(+)

/

/

/

/

/

/

/

(+)

/

/

/

BAO+IA

NP

NP

NP

TF (50)

19

50

NP

I a

/

5~7

/

12%

(+)

/

/

/

/

/

/

/

(+)

/

/

/

BAO

NP

NP

NP

TF (5)

Jimenez et al. [21]

20

55

VB

I c

23

< 1-2

/

60%

(+)

(-)

(-)

/

/

/

/

/

/

/

/

/

BAO+IA

14

Liver

SS

Alive with tumor (14)

Celyk et al. [5]

21

49

AP

III c

12

≥ 4

/

?

(+)

/

/

(+)

/

(+)

/

/

/

/

/

300

BAO+TP

36

Pelvis, liver

NP

Died (42)

McCluggage et al. [22]

22

61

AP

III c

7

12~15

/

/

(+)

/

(-)

(-)

/

(-)

/

/

(+)

/

/

196

BAO+CT

/

/

/

/

Prat et al. [2]

23

61

/

I a

10

4

/

/

/

/

/

/

/

/

/

/

/

/

/

/

BAO+RT

18

Liver

NP

Died (18)

24

59

/

II b

/

8

/

/

/

/

/

/

/

/

/

/

/

/

/

/

BAO

1

Sigmoid

SS+RT

Died (4)

25

42

/

II b

/

25

/

/

/

/

/

/

/

/

/

/

/

/

/

/

BAO

1

Ureter

RT

Alive with tumor (13)

26

65

/

I a

/

10

/

/

/

/

/

/

/

/

/

/

/

/

/

/

OR

6

Pelvis

NP

Died (13)

27

73

/

III

6

7

/

/

/

/

/

/

/

/

/

/

/

/

/

/

CT

2

Pelvis, Peritoneum

CT

Died (2)

28

49

/

I a

/

5

/

/

/

/

/

/

/

/

/

/

/

/

/

/

BAO

44

Pelvis, Peritoneum

CT

Died (48)

Fukuda et al. [23]

29

54

AP

I a

22

3~6

/

5.4%-8.2%

(+)

/

(-)

(-)

(-)

(-)

/

(+)

(+)

/

/

/

OR

14

Pelvis

SS+AP

TF (22)

Iiboshi et al. [24]

30

38

NP

I a

5.2

20~25

/

/

(+)

/

(-)

/

(-)

(-)

/

/

/

/

/

/

OR

NP

NP

NP

TF (24)

Watanabe et al. [25]

31

44

NP

IV

12

< 4

/

/

(+)

/

(+)

(-)

(-)

(-)

(-)

/

/

/

/

/

OR+RT

/

/

/

Died (4)


NP, not performed; TF, tumor-free; AP (Symptom), abdominal pain; VB, vaginal bleeding; OR, oophorectomy; BA0, a total hysterectomy with bilateral adnexectomy and an omentectomy; CT, chemotherapy; RT, radiotherapy; SS, second surgery; IA, ifosfamide + adriamycin; DTIC, dacarbazine; PVB, Cisplatin + Vincristine + Bleomycin; IAP, ifosfamide + adriamycin + Cisplatin; AP, adriamycin + Cisplatin; VP-16, etoposide; TP, paclitaxel + cisplatin

Huang et al. BMC Cancer 2010 10:585   doi:10.1186/1471-2407-10-585

Open Data